Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaip.2012.11.003 | DOI Listing |
Int J Food Microbiol
February 2025
College of Life Science, Shandong Normal University, Jinan 250358, China. Electronic address:
β-Galactosidases can be used to degrade lactose in milk to prepare lactose-free milk, which is sweeter than ordinary milk and suitable for people with lactose intolerance. The β-galactosidase gene (WcGal2809) was cloned from Weissella confusa SW1 and successfully expressed in Escherichia coli BL21(DE3). The active WcGal2809 was identified to be a heterodimer composed of two distinct proteins LacL (72.
View Article and Find Full Text PDFJ Diabetes Res
November 2024
College of Biological and Food Engineering/Key Laboratory of Research and Utilization of Ethnicinal Plant Resources of Hunan Province/Hunan Provincial Higher Education Key Laboratory of Intensive Processing Research on Mountain Ecological Food, Huaihua University, Huaihua 418000, China.
The oral safety of (Hance) Chun (sweet tea) that has antihyperglycemic potential has been verified. However, its specific application and action mechanism in the treatment of gestational diabetes mellitus (GDM) are still unclear. Total water-soluble flavonoids extracted from (Hance) Chun (sweet tea) were applied to GDM mice.
View Article and Find Full Text PDFJ Food Sci
November 2024
School of Nutrition and Food Sciences, LSU Agriculture Center, Baton Rouge, Louisiana, USA.
Plant-based yogurt alternatives (YAs) are in demand due to the societal prevalence of milk sensitivities and allergies and some consumers abstaining from animal-derived products. Producing rice flour YAs has considerable potential because rice flour is hypoallergenic, more economical compared to plant milks, and there are no commercial rice-based YAs. A new higher protein variety of rice was developed, Frontière, which is sold as both brown and white rice.
View Article and Find Full Text PDFFront Nutr
August 2024
Proteomics and Metabolomics Laboratory, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Ann Hematol
September 2024
Division of Hematology and SCT, Georgia Cancer Center, Augusta, GA, USA.
Bosutinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CML), and for patients with Ph + chronic phase, accelerated phase, or blast phase CML resistant or intolerant to prior therapy. As is the case for all TKIs approved for treatment of CML, bosutinib is associated with adverse events (AEs) that require appropriate management to ensure adherence to treatment and optimized outcomes. The aim of this review is to provide physicians with updated practical information for the prevention and management of AEs occurring during treatment with bosutinib, including dosing strategies, based on the latest published evidence and clinical experience.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!